News
At the recent SEC meeting for endocrinology and metabolism, the expert panel reviewed the proposal along with the ...
The changes will impact millions of people with type 2 diabetes in England in the biggest shake-up of care in a decade ...
5d
TipRanks on MSNAstraZeneca’s Phase I Study on Balcinrenone/Dapagliflozin: Key Insights for Investors
The study tested the effects of balcinrenone/dapagliflozin, a drug combination, both in fed and fasted states, and with the addition of quinidine, a P-gp inhibitor. The purpose is to understand how ...
3h
inews.co.uk on MSNNHS diabetes shake-up could save 22,000 lives with earlier access to weight-loss jabs
The NHS should move away from a one-size-fits-all approach of starting everyone on the same medication, to more personalised care that aims to prevent complications like heart failure and heart ...
Cookies are files saved on your phone, tablet or computer when you visit a website. We use cookies to store information about how you use the NICE website and services, such as the pages you visit.
6d
TipRanks on MSNAstraZeneca’s Latest Study on Balcinrenone/Dapagliflozin: Key Insights for Investors
Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.
5d
TipRanks on MSNAstraZeneca’s Real-World Study on Dapagliflozin: Implications for Heart Failure Treatment
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The new label for Forxiga/Farxiga (dapagliflozin) comes from the DECLARE-TIMI 58 trial, and the EU is the first major market to approve the label update, ahead of the US and China where it remains ...
AstraZeneca's Farxiga (dapagliflozin) for diabetes, heart failure, and chronic kidney disease – down 68% to $178.50; Immunex's Enbrel (aflibercept) for rheumatoid arthritis, psoriasis, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results